ADHD Market to Reach Nearly $10 Billion by 2020

August 21, 2014
The Pharm Exec staff

Pharmaceutical Executive

The Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9 billion in 2013 to $9.9 billion by 2020, with broadening diagnostic criteria a key driver of growth, according to GBI Research.

The Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9 billion in 2013 to $9.9 billion by 2020, with broadening diagnostic criteria a key driver of growth, according to GBI Research.

The company’s new report states that the increase - which represents a Compound Annual Growth Rate (CAGR) of 5.3% and relates to eight major markets (US,  UK, France, Germany, Spain, Italy, Japan and Canada) - will occur fastest in Japan, due to the country’s high ADHD prevalence.Diagnosis rates are currently low outside of the US as the disorder is still treated with considerable skepticism, says GBI Research analyst Dale Prior. But this trend is expected to change over the coming decade because of an increased recognition of adult ADHD.

The fifth edition of The Diagnostic and Statistical Manual of Mental Disorders, published last year, broadened the diagnostic criteria for ADHD, recognizing that impairment from symptoms of the disorder may develop in later life.

More information here.

Related Content:

News